Braftovi Plus Mektovi a New Combination for Unresectable or Metastatic Melanoma with BRAF Mutation

JHOP Web Exclusives - FDA Approvals, News & Updates

On June 27, 2018, the FDA approved the combination of encorafenib and binimetinib (Braftovi and Mektovi; Array BioPharma), 2 new kinase inhibitors, for the treatment of patients with unresectable or metastatic melanoma and the BRAF V600E or BRAF V600K mutation, as detected by the companion diagnostic THxID BRAF Kit, which was approved on the same day.

The approval of this new combination was based on the randomized, active-controlled, open-label, multicenter clinical trial of 577 patients with unresectable metastatic melanoma and BRAF V600E or BRAF V600K mutation. Patients were randomized to the combination of binimetinib 45 mg twice daily plus encorafenib 450 mg once daily; monotherapy with encorafenib 300 mg once daily; or monotherapy with vemurafenib (Zelboraf) 960 mg twice daily—until disease progression or unacceptable toxicity.

The median progression-free survival was 14.9 months with the binimetinib plus encorafenib combination versus 7.3 months with vemurafenib monotherapy (P <.0001). The overall response rates were 63% and 40%, respectively, and the median response duration was 16.6 months with the combination and 12.3 months in the monotherapy arm.

The most common (≥25%) adverse reactions with the encorafenib and binimetinib combination were fatigue, nausea, diarrhea, vomiting, abdominal pain, and arthralgia. Hemorrhage and headache were the most common (5%) reasons for discontinuing therapy.

Related Items
FDA News - September 2018
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in FDA Approvals, News & Updates
FDA News - May 2018
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in FDA Approvals, News & Updates
Welcome to the Third Annual Oncology Guide to New FDA Approvals
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates
FDA Approvals in 2017 Represent a 21-Year High
Gary M. Owens, MD
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates
FDA Approvals of Brand-Name Prescription Cancer Drugs in 2017
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lung Cancer
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lymphoma
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lymphoma
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Bladder Cancer
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Last modified: November 30, 2018